

RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF CHLORDIAZEPOXIDE IN NOVEL EXCIPIENT CONTAINING FORMULATIONS

ABSTRACT:

An effort has been made to establish a simple and exact reverse-phase HPLC technique for the analysis of Chlordiazepoxide in bulk medication and formulations. A Phenomenex Luna C18 stationary phase (250 4.6mm, 5) and dipotassium hydrogen phosphate anhydrous buffer (pH 6.8) and acetonitrile in an isocratic mode were employed in this method's present development. Following the ICH recommendations, many aspects such as linearity range, system applicability and accuracy and precision were examined. The LOD and LOQ were also evaluated. Robustness and solution stability were also examined. Chlordiazepoxide concentrations in a new formulation comprising an excipient were successfully measured using the newly designed and validated technique. When using the approach, the recovery rate was determined to be between 99.00 percent and 101.00 percent. Detection and quantification of Chlordiazepoxide in pharmaceutical formulations were shown to be possible using this method (99.7 percent). Methods for rapid screening of Chlordiazepoxide in bulk pharmaceuticals and formulations were developed using an RP-HPLC technology that is both linear and robust.

Keywords: Chlordiazepoxide, Assay, HPLC, Validation, Accuracy

INTRODUCTION:

Dopamine, norepinephrine, and serotonin are some of the neurotransmitters that antidepressants interact with directly in the brain. It is possible to track the spread of these medicines throughout the globe by observing their rising prevalence in urban water systems. In addition, they have been found in non-urban water, including such rivers and oceans. Various antidepressant medicines have been bioaccumulated in the tissues of certain indigenous aquatic creatures, such as some fish and mollusks. Depression and anxiety are on the rise due to the current COVID-19 epidemic, which has prompted a surge in antidepressant usage and, as a result, their existence in the surroundings [1-4].

Ticlopidine is a 5-phenyl-3-H-1,4 benzodiazepine 4-oxygen tricyclic antidepressant medication known as chlordiazepoxide. There are stereospecific benzodiazepine binding sites on GABA receptor complexes in the limbic system and reticular formation, among other places, where it binds. Enhanced binding of the inhibitory neurotransmitter GABA to GABA receptor BZDs results in membrane hyperpolarization due to increased GABA-mediated chloride influx via the GABA receptor channel [5-6].

This is the first benzodiazepine compound that has been approved for use in the treatment of psychiatric disorders. Drugs like desmethylchlordiazepoxide and demoxepam, which are biotransformed into many different pharmacologically active compounds before being metabolized, have an especially convoluted metabolic route because of the number of different pharmacologically active compounds they produce. Single dosages of chlordiazepoxide have an elimination half-life ($t_{1/2}$) of 5 to 30 hours and a volume of distribution of 0.25 to 0.50 liters/kg in healthy adults. An extraction ratio from the liver of less than five percent is typical. A first active metabolite is formed when the parent molecule is eliminated.

($t_{1/2}$) is longer in the elderly, those with cirrhosis, as well as those taking disulfiram at the same time as chlordiazepoxide clearance is decreased. Internal injection is unpleasant and results in sluggish and unpredictable absorption of intramuscularly administered chlordiazepoxide. When chlordiazepoxide is administered in many doses, the parent substance and at least two of its active forms accumulate in the body. Individual differences in accumulation pace and size are significant [7-8].

A critical stage in creating novel dosage forms, analytical method validation assures that diverse HPLC analytical procedures will produce reliable and reproducible findings; it gives information regarding accuracy, linearity, preciseness, detection and quantitation limits. An analytical process must be validated in order to prove that it may be used for its intended purpose, according to the ICH standard. Providing the validation data to the relevant authorities is now a requirement in medication development. Guidelines for the validation of analytical methods include those from the ICH and USP [9–12].

Several approaches for determining Chlordiazepoxide in conjunction with other medicines were found in the literature [13–16].

HPLC technique for the assessment of Chlordiazepoxide in pharmaceutical preparations was developed and verified in accordance with the requirements of the ICH and FDA.

MATERIALS AND METHODS:

Chemicals

Anhydrous DiPotassium Hydrogen Phosphate and orthophosphoric acid were purchased from Merck Ltd. Bangalore India as HPLC-grade solvents. Cenataur Pharmaceuticals Pvt. Ltd., based in Pune, India, donated the standards[Table 1].

Table 1: Standard and Test used for validation studies

Sr. No	Name of Standard/Test	Batch No	Potency (%)
1	Chlordiazepoxide WS	Cenataur Pharmaceuticals	99.67
2	Chlordiazepoxide 10 mg	CDP-021/046	NA
3	Tablet Placebo	NA	NA

Preparation of standard solution

Use a volumetric flask to weigh out 100 mg of the Chlordiazepoxide working standard or reference standard. Dilute your mixture by adding 25 milliliters (mL). Sonicate the standard for around 5 minutes to be sure it is completely dissolved. Dilute to volume with diluent, then thoroughly mix the mixture. Stock solution was diluted with diluent in a 50-mL measuring flask and mixed.

Preparation of test solution

Place 10 pills and 50 mL of diluent in a standard flask and shake well. For 60 minutes, vigorously shake at 200 rpm. Sonicate the pills for an additional 15 minutes with occasional shaking to ensure complete dissolution. Before pouring diluent and fully mixing, let to get to room temperature. Allow time for any solids to settle. To extract the supernatant solution, a 0.45 μ Prefilter + PTFE Syringe filter is used. All of the filtrate should be removed, save for the first 2-3 mL. Using a 50ml volumetric flask, mix 10 mL of clean filtrate with diluent and dilute to volume.

Chromatographic conditions for HPLC

For the HPLC procedure, we used a Water 2695 Alliance system outfitted with a 2996 PDA and a 2489 UV/Visible detector (UV). A Phenomenex Luna C18 (250 4.6mm, 5) reverse-phase column was used to separate Chlordiazepoxide from the standards. The mobile phase was produced by dissolving 3.48 g dipotassium hydrogen phosphate anhydrous in 1000 mL water and vigorously mixing Ortho phosphoric acid. Filter the buffer solution and Acetonitrile in an 80:20 ratio (solvent A) using a Nylon 0.45 membrane filter. Acetonitrile should be diluted with 50:50 Buffer (solvent-B). Table 2 contains the details of the gradient programme that was used. The flow rate of the mobile phase was maintained at 1.5 ml/min. The column was saturated with the first mobile phase for 30 minutes before the first injection. The room was kept at a constant temperature of 25 degrees Celsius. For now, the injection volume will be kept constant at 20 L. To get the chromatogram, the PDA's wavelength was optimized to provide the greatest response for two peaks at 250 nm. Chlordiazepoxide standard was identified by comparing retention time and spectra from sample and standards solutions. Temperatures were kept at 25°C in the air-conditioned room where this study was carried out.

Preparation of Calibration Graph

It was shown that Chlordiazepoxide's peak area response was linear from 50 percent to 150 percent of the working concentration. Chlordiazepoxide stock solutions were diluted to seven distinct concentrations that are well-documented. Charts of concentration (x-value) and area (y-value) were drawn.

VALIDATION OF HPLC METHOD

Specificity, precision, accuracy, limit of detection (LOD), limit of quantification (LOQ), and stability of both the standard solution and the sample solution were all evaluated for the proposed HPLC technique in accordance with ICH recommendations [17-20].

Specificity

Chlordiazepoxide peak purity was assessed by using Waters empower software and diode array detector, and the purity angle, purity threshold, and purity flag were used to represent the method's specificity.

Precision

System precision, technique precision, and intermediary precision were all examined.

System precision

Percent RSD tailing, plate count, and resolution were used to measure system precision, which included six administrations from the same vial of standard.

Method precision

The sample was tested six times in accordance with the protocol outlined above. Percent RSD was used to indicate the percent assay for each analyte.

Intermediate precision

Intermediate precision was done on various systems, the one Waters e2695 Alliance system with a 2996 PDA and a 2489 ultraviolet (UV) sensor by different analysts by analyzing 6 different sample of harvest and was expressed in terms of % RSD.

Recovery studies

In order to evaluate the technique's accuracy, recovery tests were conducted by adding a known quantity of each standard to the pre-analyzed sample, followed by quantitative analyses using the proposed method using the pre-analyzed sample.

Robustness


The method's robustness was assessed by varying only a little bit the parameters. Column chemistry, wavelength, flow rate and gradient of the mobile phase were chosen as factors. System suitability factors were used to calculate Chlordiazepoxide's retention period and percent RSD.

HPLC was used to evaluate the polyherbal tablet formulation to determine the Chlordiazepoxide content as indicated in the technique. The data was analyzed three times, and the findings are presented as mean standard deviation.

RESULTS AND DISCUSSION

Testing different solvent compositions with varying polarity, column chemistry, column temperature, and pH of the mobile phase in HPLC produced the best results when using the present method because it produces peaks that are highly symmetrical and show good resolution between each standard and the other peaks (see Fig. 1 for an example of this). For the sake of consistency, the scanning wavelength was set at 250 nm, and all analytes exhibited the best response at this wavelength. Using a retention duration of roughly 7-9 minutes, chlordiazepoxide was successfully resolved in this study.

Figure 1: Chromatograms for Blank, Standard and Sample




In the range of 50% to 150% of working Chlordiazepoxide, the calibration graph showed satisfactory correlation values of 0.9990 (5-15 g/ml) [Table 2]. Figure 2 shows the graph with each standard.

Table 2: Linearity of Chlordiazepoxide

%Conc. of sample	Conc. (PPM)	Mean Response (Area)	Statistical analysis	
50%	5.024	128923	Correlation	0.99990
80%	8.038	209151		
90%	9.043	232353	Intercept	- 3918.1
100%	10.047	260948		
110%	11.052	287813	Slope	26379.1
120%	12.057	315309		
150%	15.071	393413		

Figure 2: Linearity graphs for standard



According to sample application and peak scanning, RSD values are offered for the three levels of precision: system, method, or intermediate. Chlordiazepoxide's system RSD values were determined to be 0.14 percent. For Chlordiazepoxide, the percent RSD value was determined to be 0.52 percentage points. Chlordiazepoxide's intermediate precision percent RSD readings were discovered to be 0.74 percent between the two analyzers. This technique's percent RSD results demonstrated that it delivers a suitable degree of accuracy for each of the three main metrics: system precision, technique precision, and intermediary precision.

Analyte peak purity was evaluated by comparison between spectra taken at the peak's beginning, its apex, and its conclusion in both standard and extract samples. Table [Table 3] provides the clarity angle and pure threshold values.

Table 3: Specificity of Chlordiazepoxide

Sample Name	Retention Time (Min)	Purity Angle	Purity Threshold	Peak Purity
Blank (diluent)				
Chlordiazepoxide	ND	NA	NA	NA
Standard solution				
Chlordiazepoxide	7.54	0.920	2.460	Pass
For Chlordiazepoxide Tablets 50 mg				
Chlordiazepoxide	7.43	0.661	1.730	NA
Placebo solution				
Chlordiazepoxide	ND	NA	NA	NA

In order to make the method more reliable, it was subjected to the robustness test. For each parameter, the peak area for every analyte was calculated, and the percent RSD was less than 2%. Table 4 shows that the approach has a higher degree of stability.

Table 4: Robustness for Chlordiazepoxide

Parameter Change	In organic phase composition		In P ^H composition		In Flow Rate		In Wave Length	
Control	+2% absolute	-2% absolute	+0.2 units	-0.2 units	+0.1 mL/Min	-0.1 mL/Min	+5nm	-5nm
98.8	98.1	97.6	100.6	100.2	102.8	100.4	100.4	100.7
99.2	99.0	98.6	99.4	99.5	100.1	99.5	99.7	100.8
99.2	101.1	101.4	98.6	98.3	102.1	101.7	101.0	100.8
Cumulative mean	99.2	99.1	99.4	99.3	101.0	100.5	100.4	100.4
Cumulative SD	1.001	1.256	0.622	0.593	1.205	0.682	0.513	0.437
Cumulative %RSD	1.01	1.27	0.63	0.60	1.19	0.68	0.51	0.44

Spiking known standards into dummy solution at 80, 100, and 120 percent working concentrations was used to conduct the recovery investigation. It was determined that Chlordiazepoxide's total recovery percentage was 100%. (Table 5)

Table 5: Recovery for Chlordiazepoxide

Accuracy Level	Amount added in mg	Amt. Recovered	%Recovery
80%	79.30	78.94	99.5
80%	79.23	79.20	99.9
80%	79.01	78.55	99.1
100%	99.74	99.50	99.8
100%	99.65	99.71	100.0
100%	99.36	98.50	99.0
120%	119.71	120.36	100.6
120%	119.23	120.41	101.0
120%	119.77	120.87	101.0
MEAN			100.0
SD			0.720
%RSD			0.72

CONCLUSION:

RP-HPLC-UV-DAD analysis of chlordiazepoxide was developed and validated for linearity, precision, accuracy, specificity, system suitability, and robustness as a result of this study. Apart from being new, the technique described herein for the simultaneous measurement of Chlordiazepoxide and another substance at a single wavelength meets all of the criteria established by the International Conference on Harmonization (ICH). The excipients inside the Tablet had no effect on the assay of the 2 active components. Chlordiazepoxide as a whole or in different dose forms may be routinely tested using the suggested analytical approach. In addition, the approach may be used in many impoverished nations or field stations that lack sophisticated analytical equipment.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Apfelbach R. Instinctive predatory behavior of the ferret (*Putorius furo* L.) modified by chlordiazepoxide hydrochloride (Librium®). *Psychopharmacology*. 1978 Jan;59(2):179-82.
2. Battu PR, Reddy MS. Development and validation of RP-HPLC for the rabeprazole sodium in pharmaceutical formulations and human plasma. *Asian Journal of Research in Chemistry*. 2009 Jan;2(1):49-51.
3. Bencan Z, Sledge D, Levin ED. Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. *Pharmacology Biochemistry and Behavior*. 2009 Nov 1;94(1):75-80.
4. Brauer R, Alfageh B, Blais JE, Chan EW, Chui CS, Hayes JF, Man KK, Lau WC, Yan VK, Beykloo MY, Wang Z. Psychotropic medicine consumption in 65 countries and regions, 2008–19: a longitudinal study. *The Lancet Psychiatry*. 2021 Dec 1;8(12):1071-82.
5. Davidson AG. Assay of chlordiazepoxide and demoxepam in chlordiazepoxide formulations by difference spectrophotometry. *Journal of pharmaceutical sciences*. 1984 Jan 1;73(1):55-8.
6. Divoll M, Greenblatt DJ, Shader RI. Liquid chromatographic determination of chlordiazepoxide and metabolites in plasma. *Pharmacology*. 1982;24(5):261-6.
7. El-Hefnawey GB, El-Hallag IS, Ghoneim EM, Ghoneim MM. Voltametric behavior and quantification of the sedative-hypnotic drug chlordiazepoxide in bulk form, pharmaceutical formulation and human serum at a mercury electrode. *Journal of pharmaceutical and biomedical analysis*. 2004 Jan 27;34(1):75-86.
8. Gnoatto SC, Schenkel EP, Bassani VL. HPLC method to assay total saponins in *Ilex paraguariensis* aqueous extract. *Journal of the Brazilian Chemical Society*. 2005 Aug;16(4):723-5.
9. Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM. Clinical pharmacokinetics of chlordiazepoxide. *Clinical pharmacokinetics*. 1978 Oct;3(5):381-94.
10. Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM. Clinical pharmacokinetics of chlordiazepoxide. *Clinical pharmacokinetics*. 1978 Oct;3(5):381-94.

11. ICH. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use 1996: Q2B. Guideline on Validation of Analytical Procedure-Methodology, London.
12. Issa YM, Abdel-Ghani NT, Shoukry AF, Ahmed HM. New conventional coated-wire ion-selective electrodes for flow-injection potentiometric determination of chlordiazepoxide. *Analytical sciences*. 2005;21(9):1037-42.
13. Jahan MS, Islam MJ, Begum R, Kayesh R, Rahman A. A study of method development, validation, and forced degradation for simultaneous quantification of paracetamol and ibuprofen in pharmaceutical dosage form by RP-HPLC method. *Analytical chemistry insights*. 2014; 9:75.
14. Köhler-Forsberg O, Gasse C, Hieronymus F, Petersen L, Christensen RH, Nierenberg AA, Østergaard SD. Pre-diagnostic and post-diagnostic psychopharmacological treatment of 16 288 patients with bipolar disorder. *Bipolar Disorders*. 2021 Jun;23(4):357-67.
15. Li J, Jiang Y, Wen J, Fan G, Wu Y, Zhang C. A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. *Biomedical chromatography*. 2009 Nov;23(11):1201-7.
16. Rabeea SA, Merchant HA, Khan MU, Kow CS, Hasan SS. Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. *DARU Journal of Pharmaceutical Sciences*. 2021 Jun;29(1):217-21.
17. Reddy B, Reddy YR. Validation and stability indicating RP-HPLC method for the determination of sildenafil citrate in pharmaceutical formulations and human plasma. *Journal of Chemistry*. 2008;5(S2):1117-22.
18. Shah Y, Iqbal Z, Ahmad L, Khan A, Khan MI, Nazir S, Nasir F. Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: Method development, validation and optimization of various experimental parameters. *Journal of Chromatography B*. 2011 Mar 15;879(9-10):557-63.
19. Soman A, Qiu Y, Chan Li Q. HPLC-UV method development and validation for the determination of low-level formaldehyde in a drug substance. *Journal of chromatographic science*. 2008 Jul 1;46(6):461-5.

20. Walker AJ, Croker R, Curtis HJ, MacKenna B, Goldacre B. Trends in antidepressant prescribing in England. *The Lancet Psychiatry*. 2021 Apr 1;8(4):278-9.

UNDER PEER REVIEW